Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 5/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 3/20 | 0.37 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | USP14 | P54578 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27427396 | 0.77 | GSK3B (0.51) | NPC1 | |
| SCHEMBL7210582 | 0.75 | NPC1 (0.56) | NPC1CTNNB1WNT3A | |
| SCHEMBL26447291 | 0.75 | S1PR3 (0.48) | S1PR3CYP11B2CYP11B1TRPA1KCNQ3 | |
| SCHEMBL3303126 | 0.75 | GSK3B (0.49) | NPC1 | |
| SCHEMBL393951 | 0.74 | GSK3B (0.54) | S1PR3CYP11B2CYP11B1TRPA1KCNQ3 | |
| SCHEMBL26447058 | 0.74 | S1PR3 (0.50) | S1PR3CYP11B2CYP11B1TRPA1KCNQ3 | |
| SCHEMBL3215720 | 0.73 | RAB9A (0.53) | NPC1CTNNB1WNT3A | |
| SCHEMBL7285554 | 0.72 | KMO (0.45) | — | |
| SCHEMBL393075 | 0.70 | S1PR3 (0.51) | S1PR3CYP11B2CYP11B1TRPA1KCNQ3 | |
| SCHEMBL2163791 | 0.70 | S1PR3 (0.51) | S1PR3CYP11B2CYP11B1TRPA1KCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | claimed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | MKI67, CCNB1, RB1 | S1PR3 1022/4885CYP11B2 572/4885CYP11B1 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.